Analyst Viewpoint
As per the World Health Organization (WHO), cancer accounts for more than 10 million fatalities every year. Cancer-related surgeries are reported to result in post-operative nausea and vomiting, which in turn is driving the post-operative nausea and vomiting (PONV) industry growth. Moreover, the number of patients affected by anemia is increasing at a considerable rate. The year 2021 alone witnessed 1.92 billion people suffering from anemia. Increase in susceptibility of anemic patients to post-operative complications is estimated to propel the post-operative nausea and vomiting treatment market value during the forecast period.
Rise in the number of surgeries as a treatment option, surge in government initiatives for spreading awareness, and increase in focus of major pharmaceutical companies on the development of novel treatment therapies are estimated to boost the post-operative nausea and vomiting (PONV) market size in the upcoming years.
Post-operative nausea and vomiting, or PONV, is one of the most common complications following surgery, and affects up to 80% of high-risk patients. This high prevalence drives the demand for effective treatment methods and development of new drugs, such as steroids, serotonin antagonists, and dopamine antagonists, in order to provide more options to manage recovery phase vomiting and nausea.
PONV is associated with significant patient dissatisfaction. It is also associated with longer stays in post-operative care units, unanticipated hospital admission, and increased healthcare costs. Therefore, improving patient satisfaction and reducing these costs are key factors that are projected to drive the post-operative nausea and vomiting (PONV) market in 2023.
Government guidelines on the implementation of institutional protocols to manage after-surgery nausea and vomiting and stringent regulations on approval of propofol and infusions are expected to negatively impact the post-operative nausea and vomiting treatment market forecast in the near future.
Increase in number of surgeries performed across the globe is boosting the incidence of PONV, which in turn is fueling the demand for effective treatments. Moreover, growth and development of healthcare infrastructure worldwide, particularly in emerging economies, is a significant factor augmenting the post-op nausea market.
Painkillers are generally prescribed to relieve pain post a surgery. However, when it comes to mastectomy or thoracotomy or any cancer surgery, the pain could be long-term. This post-operative pain syndrome comprises nausea and vomiting apart from shivering, swelling/redness around the wound, loss of appetite. These side-effects hamper patient experience and satisfaction, which in turn is expected to impact the post-operative nausea and vomiting (PONV) market scenario during the forecast period.
Comorbidities such as renal, cardiac, pulmonary, neurological, or hepatic ailments are associated with a noticeable increase in post-operative complications. Those contracting perioperative hypoalbuminemia and anemia are at a higher risk of post-operative nausea and vomiting. Emergency surgery has higher repercussions in the form of myocardial infarction, pneumonia, major bleeding, and stroke with higher mortality.
Post-operative complications increase hospital stays for patients and could lead to further escalation is medical expenses in terms of extra treatment procedures. Furthermore, rise in aging population and increase in medical co-morbidities across the globe are expected to considerably increase the incidence of expensive postoperative complications. This, in turn, is projected to propel the demand for PONV treatment during the forecast period.
Analysis of the research report on post-operative nausea and vomiting (PONV) market reveals that North America held a prominent market share due to rise in number of surgeries performed in the U.S. As per National Center for Biotechnology Information, 40-50 million surgeries are performed in the U.S. every year. Furthermore, one of the key global market trends witnessed in the region is the growing awareness among patients about post-surgery care are their willingness to pay more to avoid post-operative complications.
According to the National Center for Biotechnology Information, nearly 20 million patients in Europe undergo major surgeries every year. It further states that more than 90% of them are either nauseated or experience vomiting sensation after surgery. These factors are projected to propel Europe’s post-operative nausea and vomiting (PONV) industry share during the forecast period.
According to the latest post-operative nausea and vomiting (PONV) market insights, the global market is highly competitive, with significant participation from both domestic and international players. Furthermore, the global market report suggests a market entry strategy for new market entrants. It also provides data that is expected to help market players to consolidate their distribution channels and expand geographical reach. A few prominent players operating in the global market include Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, GlaxoSmithKline Corporation, and Merck and Co.
Key players in the post-operative nausea and vomiting (PONV) market report have been profiled based on various parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 2.1 Bn |
| Market Forecast Value in 2031 | US$ 4.0 Bn |
| Growth Rate (CAGR) | 7.4% |
| Forecast Period | 2023-2031 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Regions Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Scope for Customization | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 2.1 Bn in 2022
It is projected to grow at a CAGR of 7.4% from 2023 to 2031
Increase in number of surgeries and surge in rate of post-operative complications
In terms of distribution channel, the hospital pharmacies segment held largest share in 2022
North America is estimated to dominate in the next few years
Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, GlaxoSmithKline Corporation, and Merck and Co.
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Post-operative Nausea and Vomiting (PONV) Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, 2022-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry
6. Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Treatment Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2023–2031
6.3.1. Serotonin Antagonists
6.3.2. Steroids
6.3.3. Dopamine Antagonists
6.3.4. NK-1 Receptor Antagonists
6.3.5. Non-pharmacologic Treatment
6.3.6. Others
6.4. Market Attractiveness, by Treatment Type
7. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2023–2031
7.3.1. Hospital Pharmacies
7.3.2. Online Pharmacies
7.3.3. Retail Pharmacies & Drug Stores
7.4. Market Attractiveness, by Distribution Channel
8. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2023–2031
9.2.1. Serotonin Antagonists
9.2.2. Steroids
9.2.3. Dopamine Antagonists
9.2.4. NK-1 Receptor Antagonists
9.2.5. Non-pharmacologic Treatment
9.2.6. Others
9.3. Market Value Forecast, by Distribution Channel, 2023–2031
9.3.1. Hospital Pharmacies
9.3.2. Online Pharmacies
9.3.3. Retail Pharmacies & Drug Stores
9.4. Market Value Forecast, by Country, 2023–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2023–2031
10.2.1. Serotonin Antagonists
10.2.2. Steroids
10.2.3. Dopamine Antagonists
10.2.4. NK-1 Receptor Antagonists
10.2.5. Non-pharmacologic Treatment
10.2.6. Others
10.3. Market Value Forecast, by Distribution Channel, 2023–2031
10.3.1. Hospital Pharmacies
10.3.2. Online Pharmacies
10.3.3. Retail Pharmacies & Drug Stores
10.4. Market Value Forecast, by Country/Sub-region, 2023–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2023–2031
11.2.1. Serotonin Antagonists
11.2.2. Steroids
11.2.3. Dopamine Antagonists
11.2.4. NK-1 Receptor Antagonists
11.2.5. Non-pharmacologic Treatment
11.2.6. Others
11.3. Market Value Forecast, by Distribution Channel, 2023–2031
11.3.1. Hospital Pharmacies
11.3.2. Online Pharmacies
11.3.3. Retail Pharmacies & Drug Stores
11.4. Market Value Forecast, by Country/Sub-region, 2023–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2023–2031
12.2.1. Serotonin Antagonists
12.2.2. Steroids
12.2.3. Dopamine Antagonists
12.2.4. NK-1 Receptor Antagonists
12.2.5. Non-pharmacologic Treatment
12.2.6. Others
12.3. Market Value Forecast, by Distribution Channel, 2023–2031
12.3.1. Hospital Pharmacies
12.3.2. Online Pharmacies
12.3.3. Retail Pharmacies & Drug Stores
12.4. Market Value Forecast, by Country/Sub-region, 2023–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2023–2031
13.2.1. Serotonin Antagonists
13.2.2. Steroids
13.2.3. Dopamine Antagonists
13.2.4. NK-1 Receptor Antagonists
13.2.5. Non-pharmacologic Treatment
13.2.6. Others
13.3. Market Value Forecast, by Distribution Channel, 2023–2031
13.3.1. Hospital Pharmacies
13.3.2. Online Pharmacies
13.3.3. Retail Pharmacies & Drug Stores
13.4. Market Value Forecast, by Country/Sub-region, 2023–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Acacia Pharma
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. F. Hoffmann-La Roche AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Ani Pharmaceuticals, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Camurus AB
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Sanofi S.A.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Helsinn Holding S.A.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Eisai Corporation
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. GlaxoSmithKline Corporation
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Merck and Co.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031
Table 02: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 03: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Region, 2023–2031
Table 04: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031
Table 05: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 06: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country, 2023–2031
Table 07: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031
Table 08: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 09: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 10: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031
Table 11: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 12: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 13: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031
Table 14: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 15: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 16: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031
Table 17: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031
Table 18: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
List of Figures
Figure 01: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031
Figure 02: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 03: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 04: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 05: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 06: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Region, 2022 and 2031
Figure 07: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Region, 2023–2031
Figure 08: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031
Figure 09: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 10: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 11: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 12: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 13: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country, 2022 and 2031
Figure 14: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country, 2023–2031
Figure 15: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031
Figure 16: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 17: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 18: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 19: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 20: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 21: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 22: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031
Figure 23: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 24: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 25: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 26: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 28: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031
Figure 30: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 31: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 32: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 34: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 35: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 36: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031
Figure 37: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 38: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031
Figure 39: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 40: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 41: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 43: Global Post-operative Nausea and Vomiting (PONV) Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Post-operative Nausea and Vomiting (PONV) Market
*86 figures and 60 tables includes